This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
JinkoSolar Holding Co., Ltd. (JKS - Free Report) reported second-quarter 2018 earnings per American Depositary Share (ADS) of 38 cents, missing the Zacks Consensus Estimate of 50 cents by 24.0%. However, the reported figure improved 90% from 20 cents in the year-ago quarter. Total Revenues In the quarter under review, JinkoSolar’s total revenues of $915.9 million missed the Zacks Consensus Estimate of $932 million by 1.
RUN ENPH FSLR
2018-08-02 fintel.io - 1
Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL) has 14 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 470,836 shares. Largest shareholders include Invesco Ltd., UBS Group AG, Bank Of America Corp /de/, Morgan Stanley, Simplex Trading, Llc, MetLife Securities, Inc, Bdo Wealth Advisors, Llc, Advisor Group, Inc.
SPWR 5GD BAC BMO UBS AEZS MS SOL FSLR BMQZF BAC SRGRF BMO AEZ HQCL ULSGF IVZ
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG) and Citigroup (C). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
FISV BRK.A C AFL DRE XOM AAPL IPGP UTX FSLR
Don't be fooled by the bad Q2 results, First Solar, by being very conservative, has built valued stability for itself in an environment that is rather volatile.
If you will forgive me, I would like to brag a little. On April 27th of this year I wrote that after a long period of bullishness on First Solar (FSLR) during which the stock gained well over 150%, I recommended not just taking a profit, but also selling FSLR short. On that day, First Solar hit a multi-year high of $81.72 and began a precipitous drop. After the market close yesterday, the company reported earnings that showed a swing to a loss in Q2, and, understandably enough, it dropped again, leaving it over 40% lower than when I made that call.
First Solar Inc. (FSLR - Free Report) reported second-quarter 2018 loss of 46 cents a share. The Zacks Consensus Estimate was pegged at a loss of a penny. The company recorded earnings of 50 cents per share in the year-ago quarter. Revenues First Solar’s revenues of $309.3 million in the quarter also lagged the Zacks Consensus Estimate of $479 million by 35.5%. Revenues declined 50.4% from the year-ago figure of $623.
EXTN EA RUN EGN NVR FSLR TRN
Investors with an interest in Solar stocks have likely encountered both JinkoSolar (JKS - Free Report) and First Solar (FSLR - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
NVR FSLR TRN
2018-07-27 seekingalpha - 4
Prescience Point’s analysis indicates that the 43.7% or 804 bps expansion in ENPH’s gross margin over the past three quarters is almost entirely attributable to potentially improper accounting.
39IB LGEPF TXN SPWR ENPH VSLR LGEAF CGIP CGI SEDG LGLD FSLR MXIM LGEJY LGEIY TSL
Earnings season is in full swing and many companies are seeing their shares face make-or-break reactions from investors. There is a growing fear that trade wars and tariffs will have an impact on earnings. Still, there are many winners.
TEAM LRCX CKRGZ CHKVP CHKDH CHKVZ SAM CMG CHKDG CHKWZ LOGM EXPE CHKDJ AMZN CHKDP CHK BJRI CHK.WI TWTR FSLR INTC
(July 26): Shares of First Solar Inc fell 6% on Thursday, after the U.S. solar company reported a surprise quarterly loss and lower-than-expected revenue due to production challenges in its next-generation panel technology.
Good afternoon, everyone, and welcome to First Solar's Second Quarter 2018 Earnings Call. This call is being webcast live on the Investors section of First Solar's website at firstsolar.com. At this time, all participants are in a listen-only mode. As a reminder, today's call is being recorded.
2018-07-27 seekingalpha - 1
The following slide deck was published by First Solar, Inc. in conjunction with their 2018 Q2 earnings call.
10h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
11h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
11h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET